All In Biotech

Drug Trial Radar · NCT02286089

Safety and Efficacy Study of OpRegen for Treatment of Advanced Dry-Form Age-Related Macular Degeneration

Phase I/IIa Dose Escalation Safety and Efficacy Study of Human Embryonic Stem Cell-Derived Retinal Pigment Epithelium Cells Transplanted Subretinally in Patients With Advanced Dry-Form Age-Related Macular Degeneration (Geographic Atrophy)

Last checked: Nov 19, 2026Latest source record: Oct 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingResults posted on the registry

Status

Active, not recruiting

Enrollment

24

Actual

Start

Apr 1, 2015

Primary completion

Dec 31, 2021

Study completion Jan 31, 2031

Sponsor

Lead sponsor
Hoffmann-La RocheRoche (Genentech) (RHHBY)
Sponsor type
Industry
First posted
Nov 7, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 50 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The main objective of the study is evaluation of the safety and tolerability of OpRegen - Human embryonic stem cell-derived retinal pigment epithelial (RPE) cells. The study will also include initial exploration of the ability of transplanted OpRegen cells to engraft, survive, and moderate disease progression.

Conditions

  • Age-Related Macular Degeneration

Interventions

  • OpRegenBiological

    Targeted dose of 50,000 - 200,000 cells will be delivered into the subretinal space.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With Treatment Emergent Adverse EventsTime frame: From study start till 12 months following last subject dosed, plus up to 90 days (up to approximately 6.5 years)
  2. Change From Baseline in Intraocular Pressure (IOP)Time frame: Baseline, Month 12

Locations

7 sites in 2 countries. Site status is shown where the registry gives one.

  • West Coast Retina Medical Group

    San Francisco, California

  • Cincinnati Eye Institute

    Cincinnati, Ohio

  • Mid Atlantic Retina

    Philadelphia, Pennsylvania

  • Hadassah Medical Center

    Jerusalem, Israel

  • Rabin Medical Center

    Petah Tikva, Israel

  • Kaplan Medical Center

    Rehovot, Israel

  • Tel Aviv Sourasky Medical Center

    Tel Aviv, Israel

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.